Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 3;5(2):216-222.
doi: 10.21873/cdp.10432. eCollection 2025 Mar-Apr.

Clinicopathological Features and Prognosis of Unresectable Colorectal Cancer With the BRAF V600E Mutation

Yukari Ono  1 , Koji Numata  1 , Kenta Iguchi  1 , Mamoru Uchiyama  1 , Masahiro Asari  1 , Yasushi Rino  2 , Aya Saito  2 , Manabu Shiozawa  1
Affiliations

Clinicopathological Features and Prognosis of Unresectable Colorectal Cancer With the BRAF V600E Mutation

Yukari Ono et al. Cancer Diagn Progn. .

Abstract

Background/aim: Patients with unresectable advanced and recurrent colorectal cancer (CRC) and the BRAF V600E mutation have poor prognosis, and conventional chemotherapy is often ineffective. This study aimed to retrospectively evaluate the clinicopathological features and prognosis of this patient population.

Patients and methods: We examined clinicopathological characteristics and treatment outcomes of 26 patients with BRAF V600E-mutated unresectable advanced and recurrent CRC treated between June 2015 and October 2022.

Results: The mean age was 63.1±14.0 years; out of 26 patients, nine (34.6%) were female, 12 (46.2%) had right-sided CRC, and eight (30.8%) had poorly differentiated or mucinous adenocarcinoma. One patient (3.8%) had a RAS mutation, and three (11.5%) had high microsatellite instability. The median overall survival (OS) was 12.0 months. The median OS for patients treated with the BEACON regimen (encorafenib plus cetuximab, with or without binimetinib) was 13.3 months, which was significantly better than that of patients treated without it (7.2 months; hazard ratio=4.180, 95% confidence interval=1.036-18.631, p=0.029). The median progression-free survival for patients treated with BEACON regimen was 6.6 months.

Conclusion: The BRAF V600E mutation was associated with poor prognosis. The BEACON regimen resulted in improved OS compared with other CRC treatment regimens.

Keywords: B-raf; BRAF V600E; Beacon CRC trial; Unresectable advanced recurrent colorectal cancer; binimetinib; encorafenib; mutation; proto-oncogene.

PubMed Disclaimer

Conflict of interest statement

The Authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Median overall survival (OS) of patients with colorectal cancer (CRC) and BRAF V600E mutation.
Figure 2
Figure 2
Median overall survival (OS) of patients treated with or without the BEACON regimen.
Figure 3
Figure 3
Median progression-free survival (PFS) of patients treated with the BEACON regimen.
See this image and copyright information in PMC

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Yokota T, Ura T, Shibata N, Takahari D, Shitara K, Nomura M, Kondo C, Mizota A, Utsunomiya S, Muro K, Yatabe Y. BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer. 2011;104(5):856–862. doi: 10.1038/bjc.2011.19. - DOI - PMC - PubMed
    1. Tabernero J, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, Desai J, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Elez E, Gollerkeri A, Maharry K, Christy-Bittel J, Kopetz S. Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study. J Clin Oncol. 2021;39(4):273–284. doi: 10.1200/JCO.20.02088. - DOI - PMC - PubMed
    1. Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T, Wasan H, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Pfeiffer P, Orlov S, Lonardi S, Elez E, Kim TW, Schellens JHM, Guo C, Krishnan A, Dekervel J, Morris V, Calvo Ferrandiz A, Tarpgaard LS, Braun M, Gollerkeri A, Keir C, Maharry K, Pickard M, Christy-Bittel J, Anderson L, Sandor V, Tabernero J. Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer. N Engl J Med. 2019;381(17):1632–1643. doi: 10.1056/NEJMoa1908075. - DOI - PubMed
    1. Hashiguchi Y, Muro K, Saito Y, Ito Y, Ajioka Y, Hamaguchi T, Hasegawa K, Hotta K, Ishida H, Ishiguro M, Ishihara S, Kanemitsu Y, Kinugasa Y, Murofushi K, Nakajima TE, Oka S, Tanaka T, Taniguchi H, Tsuji A, Uehara K, Ueno H, Yamanaka T, Yamazaki K, Yoshida M, Yoshino T, Itabashi M, Sakamaki K, Sano K, Shimada Y, Tanaka S, Uetake H, Yamaguchi S, Yamaguchi N, Kobayashi H, Matsuda K, Kotake K, Sugihara K, Japanese Society for Cancer of the Colon and Rectum Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2020;25(1):1–42. doi: 10.1007/s10147-019-01485-z. - DOI - PMC - PubMed

LinkOut - more resources